Asthma: Resource use and costs for inhaled corticosteroid vs leukotriene modifier treatment—a meta-analysis

,

Original Research

Asthma: Resource use and costs for inhaled corticosteroid vs leukotriene modifier treatment—a meta-analysis

J Fam Pract. 2003 May;52(5):382-389

By

Michael T. Halpern, MD, PhD

PDF Download

References

1. Janson S. National asthma education and prevention program, expert panel report. II: overview and application to primary care. Prim Care Pract 1998;2:578-588.

2. Lalloo UG, Bateman ED, Feldman C, et al. Guideline for the management of chronic asthma in adults—2000 update. South African Pulmonology Society Adult Asthma Working Group. S Afr Med J 2000;90:540-541-544-552.

3. Podell RN. National guidelines for the management of asthma in adults. Am Fam Physician 1992;46:1189-1196.

4. Veninga CC, Lagerlov P, Wahlstrom R, et al. Evaluating an educational intervention to improve the treatment of asthma in four European countries. Drug Education Project Group. Am J Respir Crit Care Med 1999;160:1254-1262.

5. Ozminkowski RJ, Wang S, Marder WD, Azzolini J, Schutt D. Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. Pharmacoeconomics 2000;18:253-264.

6. Paltiel AD, Fuhlbrigge AL, Kitch BT, et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. J Allergy Clin Immunol 2001;108:39-49.

7. Adams RJ, Fuhlbrigge A, Finkelstein JA, et al. Impact of inhaled antiinflammatory therapy on hospitalization and emergency department visits for children with asthma. Pediatrics 2001;107:706-711.

8. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997;277:887-891.

9. Dempsey OJ. Leukotriene receptor antagonist therapy. Postgrad Med J 2000;76:767-773.

10. Klingman D, Bielory L, Wang Y, et al. Asthma outcome changes associated with use of the leukotriene-receptor antagonist zafirlukast. Manag Care Interface 2001;14:62-66.

11. Price DB, Ben-Joseph RH, Zhang Q. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. Resp Med 2001;95:83-89.

12. Bleecker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000;105:1123-1129.

13. Ind PW. Inhaled corticosteroids versus anti-leukotrienes: a literature review on the clinical effects. Allergy 1999;54(suppl 50):43-46.

14. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999;130:487-495.

15. Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard KA. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999;103:1075-1080.

16. Stempel DA, Meyer JW, Stanford RH, Yancey SW. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol 2001;107:94-98.

17. Stempel DA, Mauskopf J, McLaughlin T, Yazdani C, Stanford RH. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001;95:227-234.

18. Cook DJ, Guyatt GH, Ryan G, et al. Should unpublished data be included in meta-analyses? Current convictions and controversies. JAMA 1993;269:2749-2753.

19. McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet 2000;356:1228-1231.

20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.

21. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990;6:5-30.

22. Oates V, Gothard L. PEER Study: New Starts on Inhaled Corticosteroids or Leukotriene Modifiers in an Asthmatic Population. Advanced Paradigm and GlaxoWellcome, Inc. July 19, 2000. Information available from GlaxoSmithKline at 1-800-825-5249.

23. Pathak DS, Davis EA, Stanford RH. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. Pharmacotherapy 2002;22:166-174.

24. Stanford R, Davis A, Edwards L, Kalberg C, Rickard K. The costs and efficacy of fluticasone propionate 88 mcg twice daily and montelukast 10 mg once daily in patients needing single controller therapy. Chest 2001;120:225S.-

25. White TJ, Gothard L, Fontes CL, Juzba M, Berenbeim DM, Gilderman AM. A Retrospective Administrative Healthcare Claims Analysis to Describe and Assess Pharmaceutical and Medical Resource Utilization within the PacifiCare CA Healthplan PROJECT 2: Longitudinal Analysis of Newly Diagnosed Asthmatics. Prescription Solutions/PacifiCare Health Systems and GlaxoWellcome Inc. November 27, 2000. Information available from GlaxoSmithKline at 1-800-825-5249.

26. Egger M, Smith GD. Meta-analysis bias in location and selection of studies. BMJ 1998;316:61-66.

27. Ebell MH. Prearrest predictors of survival following inhospital cardiopulmonary resuscitation: a meta-analysis. J Fam Pract 1992;34:551-558.

28. Poynard T, Moussalli J, Ratziu V, et al. Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Societe Royale Belge de Gastroenterologie. Acta Gastroenterol Belg 1998;61:431-437.

29. Egger M, Schneider M, Smith GD. Meta-analysis spurious precision? Meta-analysis of observational studies. BMJ 1998;316:140-144.

ABSTRACT

Objective To compare the effects of inhaled corticosteroid treatment with leukotriene modifier treatment on medical resource use and costs for asthma patients.

Study design Meta-analysis combining results from published and unpublished studies.

Data sources Studies were identified from the MEDLINE and EMBASE databases and the GlaxoSmithKline internal database study registers. Two independent reviewers evaluated the identified studies; studies meeting specified inclusion criteria were abstracted and summarized by meta-analysis with a random effects model.

Outcomes measured Hospitalization rate, emergency department visit rate, emergency department costs, drug costs, total asthma-related costs, and total medical care costs.

Results Patients taking inhaled corticosteroids had:

a significantly lower annual rate of hospitalization than those taking leukotriene modifiers (2.2% vs 4.3%, respectively;P<.05)
a greater decline in hospitalization rate (before vs after therapy initiation) than those taking leukotriene modifiers (decline of 2.4% vs 0.55%; P<.01)
a lower annual rate of emergency department visits than those taking leukotriene modifiers (6.2% vs 7.7%;P<.005).
lower total asthma-related medical costs than those taking leukotriene modifiers (P<.05) and a 17% reduction in overall total medical care costs (P not significant).

Conclusions Patients with asthma treated with inhaled corticosteroids had significantly fewer asthma-related hospitalizations and emergency department visits and lower total asthma-related health care costs than patients treated with leukotriene modifiers. These meta-analysis findings are consistent with results from randomized controlled trials showing improvements in lung function for patients taking inhaled corticosteroids as opposed to leukotriene modifiers.

Although many medications are available for patients with asthma, inhaled corticosteroids are generally the preferred treatment.^1-4 Multiple studies have demonstrated that inhaled corticosteroid therapy improves patient outcomes.¹ Inhaled corticosteroids have been shown to decrease costs⁵ and use of medical care resources.^6-8

More recently, leukotriene modifiers have been introduced for asthma treatment. This class of medication has bronchodilator and anti-inflammatory effects.⁹ Although multiple studies have indicated improved outcomes and decreased costs associated with leukotriene modifier therapy incertain patient populations,^10,11 its role in asthmamanagement is uncertain.⁹

Several studies have compared the clinical outcomes of these therapies^12-15 and their impact on medical care resource use and costs.^16,17 However, these studies were not powered specifically to detect significant differences in resource use or costs.

We performed a meta-analysis to (1) compare the rate of hospitalization among patients with asthma treated with inhaled corticosteroids vs those treated with leukotriene modifiers and (2) evaluate other resource use rates and costs for these patients.

Methods

The meta-analysis consisted of a literature search, the development of inclusion criteria, form development, and literature review.

Literature search

We searched the MEDLINE, EMBASE, Cochrane Collaboration Study Registry, and GlaxoSmithKline databases and consulted experts in this field. The GlaxoSmithKline database consists of studies sponsored by GlaxoSmithKline that met companywide minimum quality thresholds and were published in full or abstract form.

We also contacted the manufacturers of leukotriene modifiers available in the United States, AstraZeneca and Merck, to request published and unpublished information on studies comparing leukotriene modifiers with inhaled corticosteroids. To provide results corresponding to current treatment patterns, only studies from 1991 to 2001 were included. Published and unpublished materials were included.^18,19

Inclusion criteria

Studies were included in the meta-analysis if they met the following criteria.

Population. Patients with diagnosed asthma. Only studies that did not restrict analyses to severe asthma patients or children were included.

Study design. Prospective and retrospective comparative studies of patients receiving inhaled corticosteroid or leukotriene modifier monotherapy (no other controller therapy) in the same study. Studies were required to have defined inclusion and exclusion criteria, defined number of patients in each study arm, defined treatment protocol (ie, medications and doses used), and separate results for each medication.

Only studies presenting primary research (hence excluding review articles and metaanalyses) were included. Only studies presenting data for at least 6 months on all participants were included.

Outcomes. Hospitalization visit rates and costs, emergency department visit rates and costs, pharmacy costs, total asthma-related costs, and total medical care costs. Because resource use patterns and medical care cost information differs substantially between countries, we only included US studies.

Study process

Each identified article was evaluated by 2 independent reviewers (KMS and MG); any differences were discussed with a project leader to reach a consensus. Documents selected for inclusion were then reviewed by the 2 reviewers, and differences in data abstraction were resolved before inclusion.

Analysis

We used the Q statistic²⁰ to assess heterogeneity and, when appropriate, combined data from included studies with the use of a random effects model. Random effects methodology was used to assess the impact of inhaled corticosteroid vs leukotriene modifier therapy on the overall asthma population, not just the subpopulation of patients participating in included studies.²¹